StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy] (%)

Quarterly figures from Eli Lilly's filings and investor materials

QuarterlyAnnual
Latest, Q3 2024
5.0%
Period ended Sep 30, 2024
Change on a year earlier
+8.0 pts
-3.0% in Q3 2023
History
25 quarters
Since Q1 2018
Sources
25
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 20245.0%+8.0 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-4.0%-17.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024-3.0%-6.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023-9.0%-12.0 ptsEarnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-3.0%+5.0 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 202313.0%+27.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 20233.0%+7.0 ptsForm 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q4 2022Dec 31, 20223.0%+8.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022-8.0%-8.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-14.0%-19.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-4.0%-5.0 ptsForm 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q4 2021Dec 31, 2021-5.0%-21.0 ptsEarnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 20210.0%-5.0 ptsEarnings Release (Form 8-K FY2021Q3 EX-99.1) (filed 2021-10-26) ↗
Q2 2021Jun 30, 20215.0%-1.0 ptsForm 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 20211.0%-20.0 ptsForm 10-Q FY2021Q1 (filed 2021-04-30) ↗
Q4 2020Dec 31, 202016.0%–Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗

Cite this data

StockData. (2026). Eli Lilly Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q1 2018–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_cyramza_yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.